Imatinib-Induced Interstitial Pneumonitis Successfully Switched to Nilotinib in a Patient with Prior History of Mycobacterium tuberculosis Infection
نویسندگان
چکیده
Imatinib mesylate (IM) has been proven to be an effective treatment of chronic myeloid leukemia (CML) and this drug is well tolerated [1]. Interstitial lung disease (ILD) associated with imatinib therapy is rare. We report the case of a patient who had a prior treatment history of Mycobacterium tuberculosis infection and developed interstitial pneumonia after 10 months of imatinib for CML and who has not relapsed since the introduction of the recent tyrosine kinase inhibitor nilotinib.
منابع مشابه
Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection
Copyright © 2015 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. pISSN 1226-3303 eISSN 2005-664...
متن کاملSuccessful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse event of imatinib therapy. It is clinically difficult to distinguish from infectious pneumonia, wh...
متن کاملCoexistence of BCR-ABL1 Translocation and JAK2 V617F Mutation in a Patient with Chronic Myeloid Leukemia Under Long-term Treatment with Imatinib and Nilotinib: A Case Report
This report describes an 89-year-old woman diagnosed with Philadelphia positive Chronic Myeloid Leukemia in 2007 who was initially treated with 200 mg/day imatinib. The patient demonstrated complete molecular response (CMR) in two tests in 2015 and 2018. During treatment between 2007 and 2019, despite increased dosage of imatinib and switching her therapy to nilotinib, complete hematological r...
متن کاملPneumonitis due to Mycobacterium avium complex in hot tub water: infection or hypersensitivity?
We read with interest the paper by Embil et al (March 1997)1 because their first case resembled a patient we recently described in CHEST (January 1997).2 In our case, there was no doubt that we were dealing with an infection acquired from a hot tub. The patient's condition deteriorated despite discontinuation of the use of the hot tub, and dramatically improved after appropriate antimycobacteri...
متن کاملImatinib-Mesylate Induced Interstitial Pneumonitis in Two CML Patients
http://dx.doi.org/10.4046/trd.2011.71.3.210 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2011;71:210-215 CopyrightC2011. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved. Imatinib-Mesylate Induced Interstitial Pneumonitis in Two CML Patients Tae Hoon Kim, M.D., Byung Gyu Kim, M.D., Sung Woo Cho, M.D., Sung Kyun Cho, M.D., Hyun-Jung Kim, M.D., Young ...
متن کامل